Artesunate versus quinine for treating severe malaria
- 13 June 2012
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2012 (6), CD005967
- https://doi.org/10.1002/14651858.cd005967.pub4
Abstract
Background Severe malaria results in over a million deaths every year, most of them in children aged under five years and living in sub‐Saharan Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths and better treatment outcomes. Objectives To compare artesunate with quinine for treating severe malaria. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to November 2010. Selection criteria Randomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for treating adults and children with severe malaria who are unable to take medication by mouth. Data collection and analysis Two authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was all‐cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD). Where appropriate, we combined data in meta‐analyses. Main results Eight trials enrolling 1664 adults and 5765 children are included in this review. Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95% Confidence Interval (CI) 0.50 to 0.75; 1664 participants, five trials) and children (RR 0.76, 95% CI 0.65 to 0.90; 5765 participants, four trials) In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority of these sequelae were transient and no significant difference between treatments was seen at later follow up. Authors' conclusions The evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world.Keywords
This publication has 45 references indexed in Scilit:
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialThe Lancet, 2010
- Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2010
- Parasitaemia Changes in the Course of Treatment of Severe Malaria Patients with Artemether and Quinine (A Preliminary Study)Macedonian Journal of Medical Sciences, 2009
- Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trialThe Lancet, 2005
- Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised studyThe Lancet, 2004
- Randomized Comparison of Artesunate and Quinine in the Treatment of Severe Falciparum MalariaClinical Infectious Diseases, 2003
- Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Artemisinin Antimalarials in Pregnancy: A Prospective Treatment Study of 539 Episodes of Multidrug‐ResistantPlasmodium falciparumClinical Infectious Diseases, 2001
- Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1992